Detalle Publicación


Virotherapy, gene transfer and immunostimulatory monoclonal antibodies

Autores: Quetglas Más, José Ignacio; John, L.B.; Kershaw, M.H.; Alvarez-Vallina, L.; Melero Bermejo, Ignacio; Darcy, P.K.; Smerdou Picazo, Cristian
Título de la revista: ONCOIMMUNOLOGY
ISSN: 2162-4011
Volumen: 1
Número: 8
Páginas: 1345 - 1355
Fecha de publicación: 2012
Malignant cells are susceptible to viral infection and consequent cell death. Virus-induced cell death is endowed with features that are known to stimulate innate and adaptive immune responses. Thus danger signals emitted by cells succumbing to viral infection as well as viral nucleic acids are detected by specific receptors, and tumor cell antigens can be routed to professional antigen-presenting cells. The anticancer immune response triggered by viral infection is frequently insufficient to eradicate malignancy but may be further amplified. For this purpose, transgenes encoding cytokines as co-stimulatory molecules can be genetically engineered into viral vectors. Alternatively, or in addition, it is possible to use monoclonal antibodies that either block inhibitory receptors of immune effector cells, or act as agonists for co-stimulatory receptors. Combined strategies are based on the ignition of a local immune response at the malignant site plus systemic immune boosting. We have recently reported examples of this approach involving the Vaccinia virus or Semliki Forest virus, interleukin-12 and anti-CD137 monoclonal antibodies.